Chemotherapeutic cancer drugs Flashcards
Mrs. Souzoo 46/F has recently been diagnosed with papillary adenocarcinoma.
58) The gene/s that are responsible for cell proliferation and cancer formation include/s
A. p53
B. BRCA1
C. AOTA
D. NOTA
C. When mutated, the function of p53 and BRCA1 as tumor suppressor genes is lost and cells proliferate unchecked, leading to cancer. It is not the genes per se, but their mutated versions, that are implicated in cancer. Mrs. Souzoo is already diagnosed with cancer, thus we can attribute her cancer to the dysfunctional p53 and BRCA1 genes.
Factors that affect response to treatment of cancer with chemotherapy would include A. Type and size of tumor B. Belief in complementary medicine C. AOTA D. NOTA
C
Basic principles of cancer chemotherapy include the following EXCEPT
A. In cancer chemotherapy, intermittent dose schedules are generally followed to restore the drug-induced damage on bone marrow
B. Cancers with shorter mass-doubling times are more susceptible than those with longer mass-doubling times
C. Cancerous tissue possessing a small growth fraction is more susceptible than with a larger growth fraction
D. In cancer chemotherapy, optimal dosages are based upon the maximal tolerated dose
B. Shorter mass-doubling times indicate fast growth, thus it would be harder to catch the cancer at an early enough stage that would be responsive to chemotherapy.
Which of the following statements is false?
A. Paclitaxel causes disruption of mitosis
B. Methotrexate is an inhibitor of the enzyme dihydrofolate reductase
C. Cisplatin causes intra-strand cross-linking in the DNA helix
D. 5-fluorouracil, after intracellular activation, inhibits the enzyme HGPRTase
D. 5-FU inhibits thymidilate synthetase.
A major side effect associated with the use of this drug is peripheral neuropathy A. Bleomycin B. Vincristine C. Cyclophosphamide D. Doxorubicin
B. Anticancer chemotherapy handout. Vincristine is a neurotoxin and causes polyneuropathies.
In cancer chemotherapy, alkylating agents are used in combination regimens with antimetabolites to treat patients with certain cancers because they A. Do not cause hair root toxicity B. Are selectively toxic to cancer cells C. Do not damage the bone marrow cells D. Are not cell cycle specific
D. Anticancer chemotherapy handout. In combination therapy, drugs with different MOA are usually administered together because: 1) Higher response rate due to both additive or potentiated cytotoxic effects, 2) Non-overlapping host toxicities, 3) Effective against broader range cell lines in the heterogenous tumor population, 4) May slow or prevent the development of resistance.
All of the following agents show cell cycle specific cytotoxicity EXCEPT A. Methotrexate B. Mechlorethamine C. Bleomycin D. Cytarabine
B
Which of the following drugs produces ototoxicity with renal dysfunction A. Cisplatin B. Busulfan C. Hydroxyurea D. Cyclophosphamide
A
The different modalities of treatment for cancer include the following EXCEPT A. Surgery B. Chemotherapy C. Gene therapy D. NOTA
D
Which of the following anticancer drugs does not produce covalent modification of DNA or breakage of strands? A. Bleomycin B. Cisplatin C. Cyclophosphamide D. Vinblastine
D. Vinblastine just blocks mitosis.
Which of the following statements is false?
A. Doxorubicin intercalates with DNA and is also an inhibitor of the enzyme topoisomerase II
B. Methotrexate is an inhibitor of the enzyme DNA polymerase
C. Cisplatin causes intra-strand cross-linking in the DNA helix
D. 5-FU, after intracellular activation, inhibits the enzyme thymidylate synthetase
E. Paclitaxel binds to tubulin dimers and microtubulin filaments and causes disruption of mitosis
B Methotrexate is a competitive inhibitor of dihydrofolate reductase.
Cyclophosphamide
A. Acts as an inhibitor of DNA polymerase after intracellular activation
B. Acts as an alkylating agent after P450 mixed function oxidase-mediated activation
C. Produces cardiac toxicity
D. Does not cause alopecia
B. Cyclophosphamide is an alkylating agent (alkylates guanine at N7).
A major side effect associated with the use of this drug is pulmonary fibrosis A. Bleomycin B. Vincristine C. Doxorubicin D. Cyclophosphamide
A
When patients fail to respond to first-line chemotherapy, the likelihood of a response to a second-line regimen may be diminished because of:
A. Tumor cell resistance caused by multidrug resistance gene
B. Tumor cell resistance caused by selection of resistant clones
C. Increased tumor burden
D. AOTA
D
A 54 y.o. patient is being treated for leukemia. You would like to prevent the occurrence of myelosuppression which is the dose limiting toxicity for your anticancer drugs. Which among the following will you give as an adjunct to treatment? A. Metoclopramide B. Granisteron C. Granulocyte colony stimulating factor D. Interleukin
C
